{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:24:24Z","timestamp":1793391864394,"version":"4.5.0"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006312","name":"Brightfocus Foundation","doi-asserted-by":"publisher","award":["G2016027"],"award-info":[{"award-number":["G2016027"]}],"id":[{"id":"10.13039\/100006312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Institutes of Health National Eye Institute","doi-asserted-by":"publisher","award":["R01EY021205"],"award-info":[{"award-number":["R01EY021205"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Institutes of Health National Eye Institute","doi-asserted-by":"publisher","award":["T32007092"],"award-info":[{"award-number":["T32007092"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Institutes of Health National Eye Institute","doi-asserted-by":"publisher","award":["R21EY031093"],"award-info":[{"award-number":["R21EY031093"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch foundation","doi-asserted-by":"publisher","award":["F-1767"],"award-info":[{"award-number":["F-1767"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220587"],"award-info":[{"award-number":["RP220587"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recombinant antibodies are a promising class of therapeutics to treat protein misfolding associated with neurodegenerative diseases, and several antibodies that inhibit aggregation are approved or in clinical trials to treat Alzheimer's disease. Here, we developed antibodies targeting the aggregation-prone \u03b2-propeller olfactomedin (OLF) domain of myocilin, variants of which comprise the strongest genetic link to glaucoma and cause early onset vision loss for several million individuals worldwide. Mutant myocilin aggregates intracellularly in the endoplasmic reticulum (ER). Subsequent ER stress causes cytotoxicity that hastens dysregulation of intraocular pressure, the primary risk factor for most forms of glaucoma. Our antibody discovery campaign yielded two recombinant antibodies: anti-OLF1 recognizes a linear epitope, while anti-OLF2 is selective for natively folded OLF and inhibits aggregation in vitro. By binding OLF, these antibodies engage autophagy\/lysosomal degradation to promote degradation of two pathogenic mutant myocilins. This work demonstrates the potential for therapeutic antibodies to disrupt ER-localized protein aggregates by altering the fate of folding intermediates. This approach could be translated as a precision medicine to treat myocilin-associated glaucoma with in situ antibody expression. More generally, the study supports the approach of enhancing lysosomal degradation to treat proteostasis decline in glaucoma and other diseases.<\/jats:p>","DOI":"10.1093\/pnasnexus\/pgae556","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T23:11:53Z","timestamp":1733872313000},"source":"Crossref","is-referenced-by-count":4,"title":["Antibody-mediated clearance of an ER-resident aggregate that causes glaucoma"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5403-8464","authenticated-orcid":false,"given":"Minh Thu","family":"Ma","sequence":"first","affiliation":[{"name":"School of Chemistry & Biochemistry, Georgia Institute of Technology , 901 Atlantic Drive NW, Atlanta, GA 30332 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlam N","family":"Qerqez","sequence":"additional","affiliation":[{"name":"Department of Chemical Engineering, University of Texas at Austin , Austin, TX 78712 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamisha R","family":"Hill","sequence":"additional","affiliation":[{"name":"School of Chemistry & Biochemistry, Georgia Institute of Technology , 901 Atlantic Drive NW, Atlanta, GA 30332 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9423-6000","authenticated-orcid":false,"given":"Laura R","family":"Azouz","sequence":"additional","affiliation":[{"name":"Department of Chemical Engineering, University of Texas at Austin , Austin, TX 78712 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah A","family":"Youngblood","sequence":"additional","affiliation":[{"name":"School of Chemistry & Biochemistry, Georgia Institute of Technology , 901 Atlantic Drive NW, Atlanta, GA 30332 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6410-1156","authenticated-orcid":false,"given":"Shannon E","family":"Hill","sequence":"additional","affiliation":[{"name":"School of Chemistry & Biochemistry, Georgia Institute of Technology , 901 Atlantic Drive NW, Atlanta, GA 30332 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yemo","family":"Ku","sequence":"additional","affiliation":[{"name":"School of Chemistry & Biochemistry, Georgia Institute of Technology , 901 Atlantic Drive NW, Atlanta, GA 30332 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1303-7027","authenticated-orcid":false,"given":"Donna M","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, University of Wisconsin School of Medicine and Public Health , Madison, WI 53705 ,","place":["USA"]},{"name":"Department of Ophthalmology & Visual Sciences, University of Wisconsin School of Medicine and Public Health , Madison, WI 53705 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-8486","authenticated-orcid":false,"given":"Jennifer A","family":"Maynard","sequence":"additional","affiliation":[{"name":"Department of Chemical Engineering, University of Texas at Austin , Austin, TX 78712 ,","place":["USA"]},{"name":"Department of Molecular Biosciences, University of Texas at Austin , Austin, TX 78712 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9345-3735","authenticated-orcid":false,"given":"Raquel L","family":"Lieberman","sequence":"additional","affiliation":[{"name":"School of Chemistry & Biochemistry, Georgia Institute of Technology , 901 Atlantic Drive NW, Atlanta, GA 30332 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"2025012710320365100_pgae556-B1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the \u2018high-hanging fruit\u2019","volume":"17","author":"Carter","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2025012710320365100_pgae556-B2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-Amyloid-beta monoclonal antibodies for Alzheimer's disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol Psychiatry"},{"key":"2025012710320365100_pgae556-B3","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.4103\/1673-5374.239433","article-title":"Targeting prion-like protein spreading in neurodegenerative diseases","volume":"13","author":"Zhang","year":"2018","journal-title":"Neural Regen Res"},{"key":"2025012710320365100_pgae556-B4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.molmed.2008.07.004","article-title":"The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases","volume":"14","author":"Cardinale","year":"2008","journal-title":"Trends Mol Med"},{"key":"2025012710320365100_pgae556-B5","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.bbapap.2014.08.016","article-title":"Antibodies and protein misfolding: from structural research tools to therapeutic strategies","volume":"1844","author":"De Genst","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"2025012710320365100_pgae556-B6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"2025012710320365100_pgae556-B7","first-page":"1","article-title":"Editorial: the drainage of aqueous humor","volume":"14","author":"Bill","year":"1975","journal-title":"Invest Ophthalmol"},{"key":"2025012710320365100_pgae556-B8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.exer.2008.08.006","article-title":"Biological properties of trabecular meshwork cells","volume":"88","author":"Gasiorowski","year":"2009","journal-title":"Exp Eye Res"},{"key":"2025012710320365100_pgae556-B9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1006\/exer.1993.1085","article-title":"Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG)","volume":"56","author":"Rohen","year":"1993","journal-title":"Exp Eye Res"},{"key":"2025012710320365100_pgae556-B10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/hmg\/8.5.899","article-title":"Analysis of myocilin mutations in 1703 glaucoma patients from five different populations","volume":"8","author":"Fingert","year":"1999","journal-title":"Hum Mol Genet"},{"key":"2025012710320365100_pgae556-B11","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1093\/hmg\/ddh074","article-title":"Genetic dissection of myocilin glaucoma","volume":"13","author":"Gong","year":"2004","journal-title":"Hum Mol Genet"},{"key":"2025012710320365100_pgae556-B12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.exer.2008.08.011","article-title":"Glaucoma-associated myocilin: a better understanding but much more to learn","volume":"88","author":"Resch","year":"2009","journal-title":"Exp Eye Res"},{"key":"2025012710320365100_pgae556-B13","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"2025012710320365100_pgae556-B14","doi-asserted-by":"crossref","first-page":"107795","DOI":"10.1016\/j.exer.2019.107795","article-title":"Update on the genetics of primary open-angle glaucoma","volume":"188","author":"Youngblood","year":"2019","journal-title":"Exp Eye Res"},{"key":"2025012710320365100_pgae556-B15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/humu.20634","article-title":"Myocilin allele-specific glaucoma phenotype database","volume":"29","author":"Hewitt","year":"2008","journal-title":"Hum Mutat"},{"key":"2025012710320365100_pgae556-B16","first-page":"671","article-title":"Physiological function of myocilin and its role in the pathogenesis of glaucoma in the trabecular meshwork (review)","volume":"43","author":"Wang","year":"2019","journal-title":"Int J Mol Med"},{"key":"2025012710320365100_pgae556-B17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2353\/ajpath.2007.060806","article-title":"Aggregated myocilin induces russell bodies and causes apoptosis: implications for the pathogenesis of myocilin-caused primary open-angle glaucoma","volume":"170","author":"Yam","year":"2007","journal-title":"Am J Pathol"},{"key":"2025012710320365100_pgae556-B18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.bbrc.2003.10.162","article-title":"Accumulation of mutant myocilins in ER leads to ER stress and potential cytotoxicity in human trabecular meshwork cells","volume":"312","author":"Joe","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"2025012710320365100_pgae556-B19","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/hmg\/ddh128","article-title":"Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma","volume":"13","author":"Liu","year":"2004","journal-title":"Hum Mol Genet"},{"key":"2025012710320365100_pgae556-B20","doi-asserted-by":"crossref","first-page":"40661","DOI":"10.1074\/jbc.M112.384800","article-title":"Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism","volume":"287","author":"Suntharalingam","year":"2012","journal-title":"J Biol Chem"},{"key":"2025012710320365100_pgae556-B21","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1172\/JCI82799","article-title":"Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma","volume":"125","author":"Zode","year":"2015","journal-title":"J Clin Invest"},{"key":"2025012710320365100_pgae556-B22","first-page":"618","article-title":"Pro370Leu mutant myocilin disturbs the endoplasm reticulum stress response and mitochondrial membrane potential in human trabecular meshwork cells","volume":"13","author":"Wang","year":"2007","journal-title":"Mol Vis"},{"key":"2025012710320365100_pgae556-B23","first-page":"1161","article-title":"In vitro and in vivo study on the secretion of the Gly367Arg mutant myocilin protein","volume":"13","author":"Kanagavalli","year":"2007","journal-title":"Mol Vis"},{"key":"2025012710320365100_pgae556-B24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJM199810293391808","article-title":"Medical management of glaucoma","volume":"339","author":"Alward","year":"1998","journal-title":"N Engl J Med"},{"key":"2025012710320365100_pgae556-B25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"2025012710320365100_pgae556-B26","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1706193114","article-title":"CRISPR-Cas9-based treatment of myocilin-associated glaucoma","volume":"114","author":"Jain","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"633","key":"2025012710320365100_pgae556-B27","first-page":"e633.e1","article-title":"Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I\/II multicenter, controlled, multidose study","volume":"113","author":"Heier","year":"2006","journal-title":"Ophthalmology"},{"key":"2025012710320365100_pgae556-B28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ohc.2006.05.009","article-title":"Ranibizumab: phase III clinical trial results","volume":"19","author":"Rosenfeld","year":"2006","journal-title":"Ophthalmol Clin North Am"},{"key":"2025012710320365100_pgae556-B29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4103\/1673-5374.375319","article-title":"The concept of gene therapy for glaucoma: the dream that has not come true yet","volume":"19","author":"Sulak","year":"2024","journal-title":"Neural Regen Res"},{"key":"2025012710320365100_pgae556-B30","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jmb.2013.12.002","article-title":"The glaucoma-associated olfactomedin domain of myocilin forms polymorphic fibrils that are constrained by partial unfolding and peptide sequence","volume":"426","author":"Hill","year":"2014","journal-title":"J Mol Biol"},{"key":"2025012710320365100_pgae556-B31","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jmb.2011.12.016","article-title":"Amyloid fibril formation by the glaucoma-associated olfactomedin domain of myocilin","volume":"421","author":"Orwig","year":"2012","journal-title":"J Mol Biol"},{"key":"2025012710320365100_pgae556-B32","doi-asserted-by":"crossref","first-page":"12769","DOI":"10.1038\/s41598-019-48751-8","article-title":"Different Grp94 components interact transiently with the myocilin olfactomedin domain in vitro to enhance or retard its amyloid aggregation","volume":"9","author":"Huard","year":"2019","journal-title":"Sci Rep"},{"key":"2025012710320365100_pgae556-B33","doi-asserted-by":"crossref","first-page":"17951","DOI":"10.1038\/s41598-017-18344-4","article-title":"Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma","volume":"7","author":"Stothert","year":"2017","journal-title":"Sci Rep"},{"key":"2025012710320365100_pgae556-B34","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1093\/hmg\/ddu367","article-title":"Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma","volume":"23","author":"Stothert","year":"2014","journal-title":"Hum Mol Genet"},{"key":"2025012710320365100_pgae556-B35","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/hmg\/ddu730","article-title":"Structural basis for misfolding in myocilin-associated glaucoma","volume":"24","author":"Donegan","year":"2015","journal-title":"Hum Mol Genet"},{"key":"2025012710320365100_pgae556-B36","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.09.606901","article-title":"Evidence for S331-G-S-L within the amyloid core of myocilin olfactomedin domain fibrils based on low-resolution 3D solid-state NMR spectra","author":"Saccuzzo","journal-title":"bioRxiv"},{"key":"2025012710320365100_pgae556-B37","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/hmg\/6.12.2091","article-title":"Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedin-homology domain of TIGR in familial open-angle glaucoma","volume":"6","author":"Adam","year":"1997","journal-title":"Hum Mol Genet"},{"key":"2025012710320365100_pgae556-B38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.exer.2018.03.001","article-title":"Consensus recommendations for trabecular meshwork cell isolation, characterization and culture","volume":"171","author":"Keller","year":"2018","journal-title":"Exp Eye Res"},{"key":"2025012710320365100_pgae556-B39","first-page":"151","article-title":"In vitro localization of TIGR\/MYOC in trabecular meshwork extracellular matrix and binding to fibronectin","volume":"43","author":"Filla","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025012710320365100_pgae556-B40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/tra.12839","article-title":"Current methods to analyze lysosome morphology, positioning, motility and function","volume":"23","author":"Barral","year":"2022","journal-title":"Traffic"},{"key":"2025012710320365100_pgae556-B41","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.2353\/ajpath.2010.090853","article-title":"Expression of myocilin mutants sensitizes cells to oxidative stress-induced apoptosis: implication for glaucoma pathogenesis","volume":"176","author":"Joe","year":"2010","journal-title":"Am J Pathol"},{"key":"2025012710320365100_pgae556-B42","doi-asserted-by":"crossref","first-page":"12717","DOI":"10.1074\/jbc.RA119.009419","article-title":"Stable calcium-free myocilin olfactomedin domain variants reveal challenges in differentiating between benign and glaucoma-causing mutations","volume":"294","author":"Hill","year":"2019","journal-title":"J Biol Chem"},{"key":"2025012710320365100_pgae556-B43","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1093\/hmg\/8.12.2221","article-title":"A cellular assay distinguishes normal and mutant TIGR\/myocilin protein","volume":"8","author":"Zhou","year":"1999","journal-title":"Hum Mol Genet"},{"key":"2025012710320365100_pgae556-B44","first-page":"215","article-title":"The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH","volume":"22","author":"Han","year":"2009","journal-title":"Oncol Rep"},{"key":"2025012710320365100_pgae556-B45","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1080\/15548627.2015.1066957","article-title":"Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A\/SERCA-dependent autophagosome-lysosome fusion","volume":"11","author":"Mauvezin","year":"2015","journal-title":"Autophagy"},{"key":"2025012710320365100_pgae556-B46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"2025012710320365100_pgae556-B47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"2025012710320365100_pgae556-B48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2013.01.013","article-title":"Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathies","volume":"138","author":"Valera","year":"2013","journal-title":"Pharmacol Ther"},{"key":"2025012710320365100_pgae556-B49","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025012710320365100_pgae556-B50","doi-asserted-by":"crossref","first-page":"2178996","DOI":"10.1080\/27694127.2023.2178996","article-title":"Autophagy in the eye: from physiology to pathophysology","volume":"2","author":"Liton","year":"2023","journal-title":"Autophagy Rep."},{"key":"2025012710320365100_pgae556-B51","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/humu.24238","article-title":"Common and rare myocilin variants: predicting glaucoma pathogenicity based on genetics, clinical, and laboratory misfolding data","volume":"42","author":"Scelsi","year":"2021","journal-title":"Hum Mutat"},{"key":"2025012710320365100_pgae556-B52","first-page":"4028","article-title":"Prions mediated neurodegenerative disorders","volume":"19","author":"Huang","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025012710320365100_pgae556-B53","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00401-014-1375-y","article-title":"Neuropathology and biochemistry of abeta and its aggregates in Alzheimer's disease","volume":"129","author":"Thal","year":"2015","journal-title":"Acta Neuropathol"},{"key":"2025012710320365100_pgae556-B54","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci Rep"},{"key":"2025012710320365100_pgae556-B55","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/brain\/awad005","article-title":"Anti-amyloid antibody therapies in Alzheimer's disease","volume":"146","author":"Perneczky","year":"2023","journal-title":"Brain"},{"issue":"1","key":"2025012710320365100_pgae556-B56","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13024-020-00404-5","article-title":"Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer's disease","volume":"15","author":"Gibbons","year":"2020","journal-title":"Mol Neurodegener"},{"key":"2025012710320365100_pgae556-B57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","article-title":"Immunotherapy for Alzheimer's disease: targeting beta-amyloid and beyond","volume":"11","author":"Song","year":"2022","journal-title":"Transl Neurodegener"},{"key":"2025012710320365100_pgae556-B58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/JPD-202221","article-title":"Treating Parkinson's disease with antibodies: previous studies and future directions","volume":"11","author":"Castonguay","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"2025012710320365100_pgae556-B59","doi-asserted-by":"crossref","first-page":"108104","DOI":"10.1016\/j.neuropharm.2020.108104","article-title":"Tau immunotherapies: lessons learned, current status and future considerations","volume":"175","author":"Sandusky-Beltran","year":"2020","journal-title":"Neuropharmacology"},{"key":"2025012710320365100_pgae556-B60","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025012710320365100_pgae556-B61","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025012710320365100_pgae556-B62","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.1079589","article-title":"Prevention of transthyretin amyloid disease by changing protein misfolding energetics","volume":"299","author":"Hammarstrom","year":"2003","journal-title":"Science"},{"key":"2025012710320365100_pgae556-B63","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000310782","article-title":"Trabecular meshwork phagocytosis in glaucomatous eyes","volume":"211","author":"Matsumoto","year":"1997","journal-title":"Ophthalmologica"},{"key":"2025012710320365100_pgae556-B64","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/imr.12363","article-title":"TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity","volume":"268","author":"Foss","year":"2015","journal-title":"Immunol Rev"},{"key":"2025012710320365100_pgae556-B65","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025012710320365100_pgae556-B66","doi-asserted-by":"crossref","first-page":"e1700247","DOI":"10.1002\/bies.201700247","article-title":"PROTACs: an emerging targeting technique for protein degradation in drug discovery","volume":"40","author":"Gu","year":"2018","journal-title":"Bioessays"},{"key":"2025012710320365100_pgae556-B67","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.cell.2017.10.033","article-title":"A method for the acute and rapid degradation of endogenous proteins","volume":"171","author":"Clift","year":"2017","journal-title":"Cell"},{"key":"2025012710320365100_pgae556-B68","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","article-title":"The dTAG system for immediate and target-specific protein degradation","volume":"14","author":"Nabet","year":"2018","journal-title":"Nat Chem Biol"},{"key":"2025012710320365100_pgae556-B69","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ddtec.2018.12.002","article-title":"SNIPERs-hijacking IAP activity to induce protein degradation","volume":"31","author":"Naito","year":"2019","journal-title":"Drug Discov Today Technol"},{"key":"2025012710320365100_pgae556-B70","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J Am Chem Soc"},{"key":"2025012710320365100_pgae556-B71","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","article-title":"Antibody targeting of E3 ubiquitin ligases for receptor degradation","volume":"610","author":"Marei","year":"2022","journal-title":"Nature"},{"key":"2025012710320365100_pgae556-B72","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat Chem Biol"},{"key":"2025012710320365100_pgae556-B73","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s13311-013-0193-6","article-title":"Intrabodies as neuroprotective therapeutics","volume":"10","author":"Messer","year":"2013","journal-title":"Neurotherapeutics"},{"key":"2025012710320365100_pgae556-B74","doi-asserted-by":"crossref","first-page":"e68253","DOI":"10.7554\/eLife.68253","article-title":"A general approach for stabilizing nanobodies for intracellular expression","volume":"11","author":"Dingus","year":"2022","journal-title":"Elife"},{"key":"2025012710320365100_pgae556-B75","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13024-019-0340-6","article-title":"Targeting tauopathy with engineered tau-degrading intrabodies","volume":"14","author":"Gallardo","year":"2019","journal-title":"Mol Neurodegener"},{"key":"2025012710320365100_pgae556-B76","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0039-6257(02)00353-3","article-title":"Myocilin glaucoma","volume":"47","author":"Fingert","year":"2002","journal-title":"Surv Ophthalmol"},{"key":"2025012710320365100_pgae556-B77","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1350-9462(02)00010-1","article-title":"Myocilin and glaucoma: facts and ideas","volume":"21","author":"Tamm","year":"2002","journal-title":"Prog Retin Eye Res"},{"key":"2025012710320365100_pgae556-B78","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.exer.2015.08.017","article-title":"Targeting the ER-autophagy system in the trabecular meshwork to treat glaucoma","volume":"144","author":"Stothert","year":"2016","journal-title":"Exp Eye Res"},{"key":"2025012710320365100_pgae556-B79","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1021\/acschembio.7b01083","article-title":"Trifunctional high-throughput screen identifies promising scaffold to inhibit Grp94 and treat myocilin-associated glaucoma","volume":"13","author":"Huard","year":"2018","journal-title":"ACS Chem Biol"},{"key":"2025012710320365100_pgae556-B80","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/eye.2008.382","article-title":"Ocular immune privilege","volume":"23","author":"Taylor","year":"2009","journal-title":"Eye (Lond)"},{"key":"2025012710320365100_pgae556-B81","doi-asserted-by":"crossref","first-page":"10533","DOI":"10.1021\/acs.jmedchem.9b01033","article-title":"Ocular disease therapeutics: design and delivery of drugs for diseases of the eye","volume":"63","author":"Cheng","year":"2020","journal-title":"J Med Chem"},{"key":"2025012710320365100_pgae556-B82","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40259-020-00412-3","article-title":"In vivo delivery of nucleic acid-encoded monoclonal antibodies","volume":"34","author":"Patel","year":"2020","journal-title":"BioDrugs"},{"key":"2025012710320365100_pgae556-B83","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41467-017-00576-7","article-title":"An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model","volume":"8","author":"Patel","year":"2017","journal-title":"Nat Commun"},{"key":"2025012710320365100_pgae556-B84","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ymthe.2019.03.005","article-title":"In vivo delivery of a DNA-encoded monoclonal antibody protects non-human primates against Zika virus","volume":"27","author":"Esquivel","year":"2019","journal-title":"Mol Ther"},{"key":"2025012710320365100_pgae556-B85","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1038\/s41467-022-33309-6","article-title":"DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2","volume":"13","author":"Parzych","year":"2022","journal-title":"Nat Commun"},{"key":"2025012710320365100_pgae556-B86","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ymthe.2019.05.012","article-title":"mRNA delivery for therapeutic anti-HER2 antibody expression in vivo","volume":"27","author":"Rybakova","year":"2019","journal-title":"Mol Ther"},{"key":"2025012710320365100_pgae556-B87","doi-asserted-by":"crossref","first-page":"101064","DOI":"10.1016\/j.preteyeres.2022.101064","article-title":"The physiological and pathophysiological roles of the autophagy lysosomal system in the conventional aqueous humor outflow pathway: more than cellular clean up","volume":"90","author":"Shim","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"2025012710320365100_pgae556-B88","doi-asserted-by":"crossref","first-page":"dmm049816","DOI":"10.1242\/dmm.049816","article-title":"Quantitative differentiation of benign and misfolded glaucoma-causing myocilin variants on the basis of protein thermal stability","volume":"16","author":"Scelsi","year":"2023","journal-title":"Dis Model Mech"},{"key":"2025012710320365100_pgae556-B89","doi-asserted-by":"crossref","first-page":"101067","DOI":"10.1016\/j.jbc.2021.101067","article-title":"Recombinant antibodies recognize conformation-dependent epitopes of the leucine zipper of misfolding-prone myocilin","volume":"297","author":"Patterson-Orazem","year":"2021","journal-title":"J Biol Chem"},{"key":"2025012710320365100_pgae556-B90","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1073\/pnas.84.24.9150","article-title":"Structure and function of anti-DNA autoantibodies derived from a single autoimmune mouse","volume":"84","author":"Shlomchik","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025012710320365100_pgae556-B91","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/term.2488","article-title":"Characterizing differences between MSCs and TM cells: toward autologous stem cell therapies for the glaucomatous trabecular meshwork","volume":"12","author":"Snider","year":"2018","journal-title":"J Tissue Eng Regen Med"},{"key":"2025012710320365100_pgae556-B92","doi-asserted-by":"crossref","first-page":"108729","DOI":"10.1016\/j.exer.2021.108729","article-title":"Molecular architecture and modifications of full-length myocilin","volume":"211","author":"Martin","year":"2021","journal-title":"Exp Eye Res"},{"key":"2025012710320365100_pgae556-B93","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/s12859-017-1934-z","article-title":"Imagej2: ImageJ for the next generation of scientific image data","volume":"18","author":"Rueden","year":"2017","journal-title":"BMC Bioinformatics"},{"key":"2025012710320365100_pgae556-B94","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"2025012710320365100_pgae556-B95","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"}],"container-title":["PNAS Nexus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pnasnexus\/advance-article-pdf\/doi\/10.1093\/pnasnexus\/pgae556\/61023562\/pgae556.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article-pdf\/4\/1\/pgae556\/61023562\/pgae556.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article-pdf\/4\/1\/pgae556\/61023562\/pgae556.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T05:32:52Z","timestamp":1737955972000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article\/doi\/10.1093\/pnasnexus\/pgae556\/7920644"}},"subtitle":[],"editor":[{"given":"Ivet","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/pnasnexus\/pgae556","relation":{},"ISSN":["2752-6542"],"issn-type":[{"value":"2752-6542","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,12,10]]},"article-number":"pgae556"}}